Table 1 Demographics and disease characteristics of included patients (n = 198)
No. with available data | Included patients (n = 198) | |
|---|---|---|
Demographics | ||
Sex, female, no. (%) | 198 | 145 (73.2) |
Ethnicity, no. (%) | ||
White | 161 | 140 (87.0) |
Black | 161 | 16 (9.9) |
Asian | 161 | 5 (3.1) |
Age, mean ± SD, years | 198 | 51.1 ± 14.3 |
Diseases characteristics | ||
Autoantibody status a, no. (%) | ||
Anti-nuclear antibody positive | 165 | 156 (94.5) |
Anti-centromere | 152 | 43 (28.3) |
Anti-topoisomerase | 152 | 85 (55.9) |
Anti-RNAP3 | 152 | 8 (5.3) |
Anti-U1 RNP | 152 | 9 (5.9) |
Anti-PM/Scl | 152 | 6 (4.0) |
Disease duration, median (IQR), years | 198 | 0.8 (0.4; 1.2) |
Duration from RP, median (IQR), years | 187 | 1.3 (0.6; 3.9) |
Follow-up, median (IQR), years | 198 | 6.3 (3.8; 8.9) |
Skin variables | ||
Cutaneous subset, limited, no. (%) | 195 | 98 (50.3) |
mRSS, baseline, median (IQR) | 198 | 8 (2; 18) |
Baseline organ involvement, no. (%) | ||
Telangiectasia | 183 | 76 (41.5) |
Calcinosis | 175 | 20 (11.4) |
Joints | 191 | 114 (59.7) |
Muscles | 194 | 53 (27.3) |
Digital ulcers | 181 | 76 (42.0) |
Gastrointestinal tracts | 187 | 99 (52.9) |
Interstitial lung disease | 181 | 72 (39.8) |
FVC, median % (IQR) | 160 | 96.0 (76.0; 108.0) |
DLCO, median % (IQR) | 155 | 63.0 (50.0; 78.0) |
Heart | 187 | 15 (8.0) |
Pulmonary hypertension | 194 | 15 (7.7) |
Renal crisis | 123 | 12 (9.8) |
Biological variable, no. (%) | ||
Baseline CRP level, ≥ 6 mg/L | 148 | 51 (34.5) |
Treatments b, no. (%) | ||
Steroids and/or IS | 189 | 127 (68.7) |